- Home
- CMMB vs LYRA Comparison
CMMB vs LYRA Comparison
Compare CMMB & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- LYRA
- Stock Information
- Founded
- CMMB 2004
- LYRA 2005
- Country
- CMMB Israel
- LYRA United States
- Employees
- CMMB N/A
- LYRA N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- LYRA Medical/Dental Instruments
- Sector
- CMMB Health Care
- LYRA Health Care
- Exchange
- CMMB Nasdaq
- LYRA Nasdaq
- Market Cap
- CMMB 13.7M
- LYRA 11.3M
- IPO Year
- CMMB N/A
- LYRA 2020
- Fundamental
- Price
- CMMB $2.58
- LYRA $4.87
- Analyst Decision
- CMMB Strong Buy
- LYRA Hold
- Analyst Count
- CMMB 2
- LYRA 1
- Target Price
- CMMB $26.50
- LYRA $16.00
- AVG Volume (30 Days)
- CMMB 151.5K
- LYRA 28.5K
- Earning Date
- CMMB 11-12-2025
- LYRA 11-07-2025
- Dividend Yield
- CMMB N/A
- LYRA N/A
- EPS Growth
- CMMB N/A
- LYRA N/A
- EPS
- CMMB N/A
- LYRA N/A
- Revenue
- CMMB N/A
- LYRA $770,000.00
- Revenue This Year
- CMMB N/A
- LYRA N/A
- Revenue Next Year
- CMMB N/A
- LYRA $106.28
- P/E Ratio
- CMMB N/A
- LYRA N/A
- Revenue Growth
- CMMB N/A
- LYRA N/A
- 52 Week Low
- CMMB $2.39
- LYRA $3.81
- 52 Week High
- CMMB $9.84
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- CMMB 38.12
- LYRA 28.10
- Support Level
- CMMB $2.95
- LYRA $5.40
- Resistance Level
- CMMB $2.80
- LYRA $5.72
- Average True Range (ATR)
- CMMB 0.26
- LYRA 0.44
- MACD
- CMMB -0.09
- LYRA -0.14
- Stochastic Oscillator
- CMMB 2.30
- LYRA 1.82
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.